Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

significant disability when compared to patients treated with interferon beta-1a. This difference was statistically significant in favor of the alemtuzumab patients with a p-value less than the pre-specified value (p=0.01646) assigned for the three-year analysis.

Results for the secondary endpoints support the findings seen in the co- primary endpoints. Full, detailed efficacy and safety data from the study are expected to be presented at the 60th Annual Meeting of the American Academy of Neurology next spring.

"These results demonstrate the durability of the previously reported effect of alemtuzumab for the treatment of multiple sclerosis that, by our analysis, exceeds any current marketed products and anything that we can see in development," said Richard A. Moscicki, MD, chief medical officer for Genzyme. "We are very impressed with the consistency of these data and feel that they continue to point to the strong likelihood of alemtuzumab being approved for MS patients."

Safety Data: No New Cases of ITP

A total of six patients have been diagnosed with ITP associated with Grade 3 or 4 thrombocytopenia in this trial and there have been no new cases of ITP reported in the past year in this study.

Common non-serious adverse events included infusion reactions in the alemtuzumab patients and flu-like symptoms in patients using interferon beta- 1a. Severe infections were infrequent in the alemtuzumab patients and were resolved with or without an intervention. The incidence of all thyroid adverse events, including Graves' disease, was less than expected compared to early reports in the literature on the use of alemtuzumab in MS.

Two Phase 3 studies have recently begun examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis. Genzyme and Bayer Schering Pharma AG, Germany announced last month the start of the CARE-MS I trial (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis), a randomized
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
(Date:5/23/2013)... Calif. , May 23, 2013 Amgen (NASDAQ: ... 38 th Annual  Healthcare Conference on Thursday, May 30, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... at Amgen, will present at the conference. Live audio of ... Amgen,s website, www.amgen.com , under Investors. A replay of ...
(Date:5/23/2013)... , May 23, 2013  A recently published ... Houston, Texas , demonstrates that 3D ... increasing cancer detection. The study, "Implementation ... Observational Study," was led by Stephen L. ... issue of the American Journal of Roentgenology ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... Mylan Inc. (Nasdaq: MYL ) today ... Laboratories Limited) has received final approval from the U.S. ... Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, ... is the generic version of Pfizer,s Lipitor® Tablets, which ...
... May 29, 2012 Ranbaxy Laboratories Inc. (RLI), a ... announced today that the U.S. Food and Drug Administration ... of the acne medication isotretinoin, for the treatment of ... the Canadian firm, Cipher Pharmaceuticals Inc., RLI is expected ...
Cached Medicine Technology:Mylan Launches Generic Version of Lipitor® 2Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA 2
(Date:5/25/2013)... 25, 2013 Imagine running the air conditioner ... loss, hot air and wasted energy! If the home has ... fireplace or clothes dryer, that may be just what is ... often overlooked holes waste energy in the form of higher ... cooling loss in the home. , Drafts occur through the ...
(Date:5/25/2013)... Dr. Leslie Gerstman announced today that Ultherapy ... the neck, on the brow and under the chin -- ... is a non-surgical procedure for the face and neck that ... skin over time. The use of FDA-cleared ultrasound technology enables ... the deepest support layers of the skin – typically addressed ...
(Date:5/25/2013)... Communities of Distinction TV announces May air ... media market in the United States with almost three million ... Texas and a major convention city. Ft. Worth is known ... is home to many major museums. Both cities offer a ... arts. Residents and locals will be able to watch the ...
(Date:5/25/2013)... Many viruses and parasites that affect both dogs and ... illness than can result in liver or kidney failure ... a veterinarian. These germs could be found ... Dr. Susan Nelson, a clinical associate professor at Kansas ... diseases can be fatal, even with treatment," she said ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Radius ... underground shelter company in the US and has ... structures for over 35 years. M.E. and President, ... Handbook of NBC Weapon Fundamentals and Shelter Engineering ... States’ bible on shelter engineering. McCarthy is considered ...
Breaking Medicine News(10 mins):Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Hidden Dangers Dog Dog Parks 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3
... MADISON Most cancers are easier to treat if ... screening and prompt treatment. But for immigrants and other ... early detection even if it,s been translated into ... "Medical interventions fail if the intervention does not match ...
... Minn. -- Mayo Clinic investigators, with Belgian collaborators, have ... effectively heal, repair and regenerate damaged heart tissue. The ... -- appear in today,s Journal of the American ... from patients have normally a limited capacity to repair ...
... News) -- The massive BP oil spill in the Gulf ... fishermen and members of coastal communities, according to a group ... be aware of, and look for, evidence of toxicity from ... asked about occupation and location of residence, the physical examination ...
... associated with cancer progression when abundant inside of tumors ... that feed the tumor outside, a research team led ... Cancer Center reports in the August edition of ... to block production of the protein, the researchers inhibited ...
... of potential health risks posed by secondhand tobacco smoke, ... of using ozone to remove the smell of tobacco ... interiors of vehicles, is probably a bad idea. ... Berkeley National Laboratory (Berkeley Lab) shows that ozone can ...
... Gothenburg, Sweden, have for the first time identified 12 ... The discovery could result in more reliable prognoses and ... in the journal Clinical Cancer Research , are ... breast cancer patients. Half of these patients died within ...
Cached Medicine News:Health News:Building a bridge with cross-cultural cancer education 2Health News:Building a bridge with cross-cultural cancer education 3Health News:Mayo's 'smart' adult stem cells repair hearts 2Health News:Gulf Oil Spill Still a Health Threat to Many, Researchers Report 2Health News:Gulf Oil Spill Still a Health Threat to Many, Researchers Report 3Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 2Health News:Novel role: EZH2 boosts creation of ovarian cancer blood vessels 3Health News:Berkeley study shows ozone and nicotine a bad combination for asthma 2Health News:Berkeley study shows ozone and nicotine a bad combination for asthma 3Health News:Genes associated with aggressive breast cancer 2
... Conforming to U.S. and international engineering ... TC-100 Screw and Plating System* provides ... ease of use for open reduction ... the TC-100 system works well beyond ...
... The CARDIA PFO Occluder ... transvenous closure of Patent Foramen ... sheaths (10-12F) the device offers ... for the percutaneous closure of ...
Half pin skeletal traction pins with cove point....
Round Bevel-Point Pin Sets available in 2.3mm, 3.1mm, 4.7mm, and 6.3mm sizes....
Medicine Products: